These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1674161)

  • 41. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.
    Gur RE; Maany V; Mozley PD; Swanson C; Bilker W; Gur RC
    Am J Psychiatry; 1998 Dec; 155(12):1711-7. PubMed ID: 9842780
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher fundamental voice frequency is related to extrapyramidal symptoms in schizophrenia.
    Graux J; Courtine JB; Bruneau N; Camus V; El-Hage W
    Schizophr Res; 2015 Feb; 161(2-3):517-8. PubMed ID: 25468179
    [No Abstract]   [Full Text] [Related]  

  • 43. Extrapyramidal motor abnormalities associated with late-life psychosis.
    Caligiuri MP; Lohr JB; Panton D; Harris MJ
    Schizophr Bull; 1993; 19(4):747-54. PubMed ID: 7905662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
    Dieterle DM; Ackenheil M; Müller-Spahn F; Kapfhammer HP
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):52-7. PubMed ID: 2883683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of neuroleptic treatment on positive and negative symptoms of schizophrenia and the results of the dexamethasone test].
    Rybakowski J; Linka M
    Psychiatr Pol; 1991; 25(1):1-6. PubMed ID: 1685787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
    Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
    Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia].
    Tiganov AS; Panteleeva GP; Abramova LI; Bologov PV; Kananovich PS; Omel'chenko MA; Nikiforova IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):72-80. PubMed ID: 28374697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
    Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relation of plasma prolactin to clinical response in schizophrenic patients.
    Gruen PG; Sachar EJ; Altman N; Langer G; Tabrizi MA; Halpern FS
    Arch Gen Psychiatry; 1978 Oct; 35(10):1222-7. PubMed ID: 29592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients.
    Shopsin B; Pearson E; Gershon S; Collins P
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):739-48. PubMed ID: 4629112
    [No Abstract]   [Full Text] [Related]  

  • 60. Results of an open phase II study with zotepine--a new neuroleptic compound.
    Fleischhacker WW; Unterweger B; Barnas C; Stuppäck C; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):64-6. PubMed ID: 2883686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.